Go Pro
→ Shocking AI prediction from the “Billionaire Whisperer' (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:IMDX

Oncocyte Q3 2025 Earnings Report

Oncocyte logo
$4.20 +0.22 (+5.53%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$4.20 +0.00 (+0.12%)
As of 09/11/2026 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Oncocyte EPS Results

Actual EPS
-$0.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oncocyte Revenue Results

Actual Revenue
$0.26 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Oncocyte Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Oncocyte Earnings Headlines

iMDx to Participate in Lake Street 10th Annual Best Ideas Growth “BIG10” Conference
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355088/0/en/imdx-to-participate-in-lake-street-10th-annual-best-ideas-growth-big10-conference.html
Insight Molecular Diagnostics Inc. (IMDX) Discusses Advances in Heart Transplant Rejection Testing and Evolution of Diagnostic Methods Transcript
August 17, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4937395-insight-molecular-diagnostics-inc-imdx-discusses-advances-in-heart-transplant-rejection
Gold led me to Mount Rushmore
A small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technology. This could be one of the biggest gold finds since the 1870s, yet the stock still trades around 6 dollars. BlackRock and Vanguard have been quietly loading up on shares while most investors have missed the story. The same technology is unlocking hidden resource wealth across America, driving stocks up 227 percent, 378 percent, and even 773 percent.tc pixel
September 12 at 1:00 AM  |  Stansberry Research (Ad)
Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing
August 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/11/3343161/0/en/insight-molecular-diagnostics-to-host-virtual-kol-event-on-august-17-2026-moving-toward-in-house-heart-transplanted-organ-rejection-testing.html
Insight Molecular Diagnostics Inc. (IMDX) Q2 2026 Earnings Call Transcript
August 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4934501-insight-molecular-diagnostics-inc-imdx-q2-2026-earnings-call-transcript
iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference
August 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/04/3338155/0/en/imdx-to-release-second-quarter-results-on-august-10-2026-and-attend-needham-virtual-medtech-diagnostics-1x1-conference.html
See More Oncocyte Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oncocyte? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncocyte and other key companies, straight to your email.

About Oncocyte

Oncocyte (NASDAQ:IMDX) (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows. Its offerings are positioned to support physicians by reducing diagnostic uncertainty, guiding the need for invasive procedures, and helping to prioritize patients for additional testing or treatment. The company pursues clinical validation and regulatory review as part of its path to broader commercial adoption.

Headquartered in the United States, Oncocyte distributes its tests through clinical laboratory networks and strategic partnerships aimed at reaching physicians and healthcare systems. As a publicly listed company on the NASDAQ (IMDX), it concentrates on advancing its diagnostic pipeline, expanding commercial operations, and engaging with payors and clinical stakeholders to integrate its assays into standard oncology care pathways. Information on individual executives and recent leadership changes should be confirmed from the company’s filings and official communications for the most current details.

View Oncocyte Profile
Earnings Tools